Opioid Use Disorder Market Growth Opportunities and Revenue Analysis 2034
Opioid Use Disorder Market Growth Opportunities and Revenue Analysis 2034
The Opioid Use Disorder (OUD) is a complex disorder market growth in 2026 characterized by the compelling use of opioid drugs, even when an individual wants to stop using them or when opioid use negatively affects emotional and physical well-being. Treatment for OUD includes three major drug classes: buprenorphine, methadone, and naltrexone. These drug classes are approved by the U.S. FDA for medication treatment of the disorder.
According to Fortune Business Insights, the global Opioid Use Disorder (OUD) market size was valued at USD 3.92 billion in 2025. The market is projected to grow from USD 4.26 billion in 2026 to USD 9.27 billion by 2034, exhibiting a CAGR of 10.20% during the forecast period. North America dominated the opioid use disorder market with a market share of 77.59% in 2025.
The increasing number of people experiencing chronic diseases and requiring pain management has contributed to the use of opioid-based painkillers. As dependence on these medicines increases, the need for effective opioid use disorder treatments is also expanding. Governments and organizations are increasingly focusing on addressing opioid dependence, improving awareness, and expanding access to treatment programs.
Growing Opioid Addiction Cases: The increasing prevalence of opioid use and dependence is creating a greater need for treatment solutions. Chronic diseases requiring pain management and the use of opioid-containing painkillers are among the factors contributing to opioid dependence.
Government Awareness Initiatives: Governmental and non-governmental organizations are increasing efforts to address opioid overdose, improve awareness, and expand access to medication-assisted treatment. Such initiatives are expected to encourage more individuals with opioid-related disorders to seek treatment.
Demand for Buprenorphine Treatments: Growing consideration of buprenorphine products, including long-acting treatment options and transdermal patches, is supporting market development.
Adverse Effects of OUD Drugs: Side effects associated with OUD treatment drugs may restrict market expansion. Reported adverse reactions include muscle aches, vomiting, diarrhea, constipation, respiratory issues, bone and joint pain, bladder pain, and abdominal cramps.
Regulatory Concerns: Warnings related to certain treatment medicines may affect their adoption. In January 2022, the U.S. FDA warned about dental problems associated with buprenorphine medicines dissolved in the mouth for treating OUD and pain.
Increasing consideration of buprenorphine patches represents an important trend in the market. Transdermal patches can simplify drug delivery and may provide reduced pain compared with conventional approaches. They can also serve as a potential alternative for patients requiring around-the-clock opioid therapy. Collaborations and clinical research aimed at developing additional treatment options are expected to support adoption during the forecast period.
The competitive landscape includes prominent companies such as Indivior PLC, Alkermes, and Orexo AB. These companies have strong product portfolios covering buprenorphine and naltrexone products and are involved in research and development activities focused on opioid disorder treatments, including long-acting buprenorphine.
Indivior PLC has multiple buprenorphine products in its portfolio, including SUBLOCADE and SUBOXONE. Orexo AB and Alkermes also have extensive product offerings. Companies are pursuing strategies including collaborations and new product launches to expand their presence in the market.
Indivior PLC (U.S.)
Alkermes (Ireland)
Orexo AB (Sweden)
Titan Pharmaceuticals, Inc. (U.S.)
Mallinckrodt Pharmaceuticals (U.K.)
BioDelivery Sciences International Inc. (U.S.)
Viatris Inc. (Mylan N.V.) (U.S.)
Hikma Pharmaceuticals PLC (U.K.)
Camurus (Sweden)
By Drug Class (Buprenorphine, Methadone, and Naltrexone)
By Route of Administration (Oral and Parenteral)
By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Stores, and Online Pharmacies)
Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/opioid-use-disorder-oud-market-102674
North America: The region dominated the market with a 77.59% share in 2025. The market was valued at USD 3.04 billion in 2025 and is estimated to reach USD 3.31 billion in 2026, supported by treatment infrastructure, opioid dependency cases, key market players, and government involvement.
Europe: Europe accounted for 10.98% of the global market in 2025, reaching USD 0.43 billion. The regional market is projected to reach USD 0.46 billion in 2026, supported by new product launches and increasing opioid dependency.
Asia Pacific: The market reached USD 0.33 billion in 2025 and represented 8.47% of global revenue. It is projected to reach USD 0.37 billion in 2026, supported by rising awareness and increasing healthcare spending.
Increasing opioid dependency, greater awareness, government involvement, new product launches, and demand for effective therapeutics are expected to support future market development. Buprenorphine is expected to remain the leading drug class, while parenteral administration is projected to maintain its leading position by route of administration. The growing number of opioid treatment programs and continued development of treatment products are also expected to contribute to market expansion.
Uncover Japan’s Market Trends - Explore the Latest -Opioid Use Disorder Market- Insights